BlueSphere Bio
BlueSphere Bio is a Pittsburgh-based immunotherapy company developing novel T-cell therapies to treat individuals diagnosed with liquid and solid tumors. Their mission is to rapidly screen, identify, and validate TCR-based therapies for accelerated delivery to the clinic, aiming to give every cancer patient a chance for a cure. They focus on innovative platform technologies like TCXpress™ and NeoXPress™ to advance their pipeline of personalized cancer treatments.
Industries
Nr. of Employees
small (1-50)
BlueSphere Bio
Pittsburgh, Pennsylvania, United States, North America
Products
Engineered TCR T-cell therapy program targeting blood-restricted antigens paired with allogeneic stem cell transplant
Pipeline of engineered T cell receptor therapies directed at blood-restricted antigens designed to be administered in conjunction with allogeneic CD34+ stem cell transplantation for hematologic malignancies.
Autologous engineered TCR T-cell program targeting NPM1-derived neoantigens
Autologous TCR-engineered T-cell program targeting neoantigens generated by mutant NPM1 in acute myeloid leukemia; lead candidate progressing through IND-enabling studies.
High-throughput TCR discovery platform (integrated capture, single-cell, and analysis)
Integrated discovery platform combining automated capture, single-cell sequencing/characterization and bioinformatics pipelines to identify antigen-specific TCRs for therapeutic development.
Engineered TCR T-cell therapy program targeting blood-restricted antigens paired with allogeneic stem cell transplant
Pipeline of engineered T cell receptor therapies directed at blood-restricted antigens designed to be administered in conjunction with allogeneic CD34+ stem cell transplantation for hematologic malignancies.
Autologous engineered TCR T-cell program targeting NPM1-derived neoantigens
Autologous TCR-engineered T-cell program targeting neoantigens generated by mutant NPM1 in acute myeloid leukemia; lead candidate progressing through IND-enabling studies.
High-throughput TCR discovery platform (integrated capture, single-cell, and analysis)
Integrated discovery platform combining automated capture, single-cell sequencing/characterization and bioinformatics pipelines to identify antigen-specific TCRs for therapeutic development.
Expertise Areas
- T cell receptor discovery and development
- T-cell engineering for autologous cell therapies
- Bispecific protein and antibody engineering
- Single-cell genomics and NGS workflows
Key Technologies
- Next-generation sequencing (NGS) and single-cell RNA-seq
- T cell receptor search and capture platforms
- Parallelized capture workflows and scalable analysis pipelines
- Lentiviral vector production and banking